





PTO/SB/08b (04-09)

Approved for use through 05/31/2009. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/752,423
Filing Date	January 6, 2004
First Named Inventor	Erik Buntinx
Art Unit	1617
Examiner Name	Umamaheswari Ramachandran
Attorney Docket Number	29248/19

Sheet 2 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	4	VAN OEKELLEN D et al., "Different regulation of rat 5-HT _{2A} and rat 5-HT _{2C} receptors in NIH 3T3 cells upon exposure to 5-HT and pipamperone," European Journal of Pharmacology 425 (2001) 21-32.	
	5	Meyer U A, "Overview of Enzymes of Drug Metabolism," Journal of Pharmacokinetics and Biopharmaceutics, Vol. 24, No. 5, 1996, 449-459.	
	6	MOORE N et al., "Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder," Int Clin Psychopharmacol 20:131-137, 2005.	
	7	MONTGOMERY S A et al., "Escitalopram versus venlafaxine XR in the treatment of depression," International Clinical Psychopharmacology 2006, 21:297-309.	
	8	KHAN A et al., "Symptom Reduction and Suicide Risk in Patients Treated with Placebo in Antidepressant Clinical Trials," Arch Gen Psychiatry, Vol. 57, April 2000, 311-317.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.